Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]I. Brana, J. Tabernero: Cardiotoxicity. Ann Oncol 21, 173-179 (2010)

  • [2]M.S. Ewer, S.M. Swain, D. Cardinale, A. Fadol, T.M. Suter: Cardiac dysfunction after cancer treatment. Tex Heart Inst J 38, 148-252 (2011)

  • [3]G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, L. Gianni: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56, 185-229 (2004)

  • [4]J.L. Zamorano, P. Lancellotti, D. Rodriguez Muñoz, V. Abonyas, R. Asteggiano, M. Galderisi, G. Habib, D.J. Lenihan, G.Y. Lip, A.R. Lyon, T. Lopez Fernandez, D. Mothy, M.F. Piepoli, J. Tamargo, A. Torbicki, T.M. Suter, Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG): 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J 37, 2768-2801 (2016)

  • [5]A. Albini, G. Pennesi, F. Donatelli, R. Cammarota, S. De Flora, D.M. Noonan: Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102, 14-25 (2010)

  • [6]J.G. Blanco, C.L. Sun, W. Landier, L. Chen, D. Esparza-Duran, W. Leisenring, A. Mays, D.L. Friedman, J.P. Ginsberg, M.M. Hudson, J.P. Neglia, K.C. Oeffinger, A.K. Ritchey, D. Villaluna, M.V. Relling, S. Bhatia: Anthracycline related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes - a report from the Children’s Oncology Group. J Clin Oncol 30, 1415-1421 (2012)

  • [7]M.W. Bloom, C.E. Hamo, D. Cardinale, B. Ky, A. Nohria, L. Baer, H. Skopicki, D.J. Lenihan, M. Gheorghiade, A.R. Lyon, J. Butler: Cancer therapy-related cardiac dysfunction and heart failure - Part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail 9, e002661 (2016)

  • [8]P.G. Camici, F. Crea: Coronary microvascular dysfunction. N Engl J Med 356, 830-840 (2007)

  • [9]F. Crea, P.G. Camici, C.N. Bairey Merz: Coronary microvascular dysfunction: an update. Eur Heart J 35,1101-1111 (2014)

  • [10]A. Sestito, G.A. Lanza, A. Di Monaco, P. Lamendola, G. Careri, P. Tarzia, G. Pinnacchio, I. Battipaglia, F. Crea: Relation between cardiovascular risk factors and coronary microvascular dysfunction in cardiac syndrome X. J Cardiovasc Med 12, 322-327 (2011)

  • [11]J. Escaned, A. Flores, P. García-Pavía, J. Segovia, J. Jimenez, P. Aragoncillo, C. Salas, F. Alfonso, R. Hernàndez, D.J. Angiolillo, P. Jiménez-Quevedo, C. Bañuelos, L. Alonso-Pulpón, C. Macaya: Assessment of microcirculatory remodeling with intracoronary flow velocity and pressure measurements: validation with endomyocardial sampling in cardiac allografts. Circulation 120, 1561-1568 (2009)

  • [12]D.Y. Leung, M. Leung M. Non-invasive/invasive imaging: significance and assessment of coronary microvascular dysfunction. Heart 97, 587-595 (2011)

  • [13]P. Rajendran, T. Rengarjan, J. Thangavel, Y. Nishigaki, D. Sakthisekaran, G. Sethi, I. Nishigaki: The vascular endothelium and human diseases. Int J Biol Sci 9, 1057-1069 (2013)

  • [14]N.D. Roe, J. Ren: Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vascul Pharmacol 57, 168-172 (2012)

  • [15]D.C. Sane, L. Anton, K.B. Brosnihan: Angiogenic growth factor and hypertension. Angiogenesis 7, 193-201 (2004)

  • [16]F. Perticone, A. Sciacqua, R. Maio, M. Perticone, R. Maas, R.H. Boger, G. Tripepi, G. Sesti, C. Zoccali: Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46, 518-523 (2005)

  • [17]A. Durante, G. Peretto, A. Laricchia, F. Ancona, M. Spartera, A. Mangieri, D. Cianflone: Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des 18, 981-1004 (2012)

  • [18]M.B. Wolf, J.W. Baynes. The anti-cancer drug, doxorubicin, causes oxidant stress induced endothelial dysfunction. Biochim Biophys Acta 1760, 267-271 (2006)

  • [19]L. Morbidelli, S. Donnini, M. Ziche: Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents. Cardiooncology, DOI: 10.1.186/s40959-016-0010-6 (2016)

  • [20]S. Kinhult, M. Albertsson, J. Eskilsson, M. Cwikici: Effects on probucol on endothelial damage by 5-fluorouracil. Acta Oncol 42, 304-308 (2003)

  • [21]B.L. Samuels, N.J. Vogelzang, B.J. Kennedy. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 19, 253-256 (1987)

  • [22]H. Hurwitz, L. Fehrenbacher. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342 (2004)

  • [23]A. Soultati, G. Mountzios, C. Avgerinou, G. Papaxoinis, D. Pectasides, M.A. Dimopoulos, C. Papadimitriou: Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev 38, 473-483 (2012)

  • [24]Harrison DG: Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100, 2153-2157 (1997)

  • [25]A. Mügge, J.H. Elwell, T.E. Peterson, T.G. Hofmeyer, D.D. Heistad, D.G. Harrison: Chronic treatment with polyethylene glycolated superoxide dismutase partially restores endotheliumdependent vascular relaxations in cholesterol-fed rabbits. Circ Res 69, 1293-1300 (1991)

  • [26]T. Heitzer, H. Just, T. Munzel: Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 94, 6-9 (1996)

  • [27]T. Kamba, D.M. McDonald: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96, 1788-1795 (2007)

  • [28]J.R. Vane, E.E. Anggard, R.M. Botting: Regulatory functions of the vascular endothelium. N Engl J Med 323, 27-36 (1990)

  • [29]P.G. Camici, G. d’Amati, O.E. Rimoldi: Coronary microvascular dysfunction: mechanisms and functional assessment. Nat Rev Cardiol 12, 48-62 (2015)

  • [30]Chayama: Response of the left anterior descending coronary artery to acetylcholine in patients with chest pain and angiographically normal coronary arteries. Am J Cardiol 92, 1394-1398 (2003)

  • [31]P. Libby, P.M. Ridker, G.K. Hansson: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54, 2129-2138 (2009)

  • [32]P. McGale, S.C. Darby, P. Hall, J. Adolfsson, N.O. Bengtsson, A.M. Bennet, T. Fornander, B. Gigante, M.B. Jensen, R. Peto, K. Rahimi, C.W. Taylor, M. Ewertz: Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 100, 167-175 (2011)

  • [33]F.C. Brosius 3rd, B.F. Waller, W.C. Roberts: Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 70, 519-530 (1981)

  • [34]M. Florescu, M. Cinteza, D. Vinereanu: Chemotherapy-induced cardiotoxicity. Maedica 8, 59-67 (2013)

  • [35]H.S. Haugnes, T. Wethal, N. Aass, O. Dahl, O. Klepp, C.W. Langberg, T. Wilsgaard, R.M. Bremnes, S.D. Fossa. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 28, 4649-4657 (2010)

  • [36]P. Rouet-Benzineb, B. Gontero, P. Dreyfus, C. Lafuma: Angiotensin II induces nuclear factor- kappa B activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol 32, 1767-1778 (2000)

  • [37]A.J. Naftilan, R.E. Pratt, V.J. Dzau VJ: Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 83, 1419-1424 (1989)

  • [38]R.T. Lee, F.J. Schoen, H.M. Loree, M.W. Lark, P. Libby: Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis: implications for plaque rupture. Arterioscler Thromb Vasc Biol 16, 1070-1073 (1996)

  • [39]B. Furie, B.C. Furie: Mechanisms of thrombus formation. N Engl J Med 359, 938-949 (2008)

  • [40]R.A. Moore, N. Adel, E. Riedel, M. Bhutani, D.R. Feldman, N.E. Tabbara, G. Soff, R. Parameswaran, H. Hassoun: High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29, 3466-3473 (2011)

  • [41]D. Cameron, J. Brown, R. Dent, C. Jackisch, J. Mackey, X. Pivot, G.G. Steger, T.M. Suter, M. Toi, M. Parmar, R. Laeufle, Y.H. Im, G. Romieu, V. Harvey, O. Lipatov, T. Pienkowski T, P. Cottu, A. Chan A, S.A. Im, P.S. Hall, L. Bubuteishvili-Pacaud, V. Henschel, R.J. Deurloo, C. Pallaud, R. Bell: Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14, 933-942 (2013)

  • [42]F.A. Scappaticci, J.R. Skillings, S.N. Holden, H.P. Gerber, K. Miller, F. Kabbinavar, E. Bergsland, J. Ngai, E. Holmgren, J. Wang, H. Hurwitz. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99, 1232-1239 (2007)

  • [43]I. Porto, F. Belloni, G. Niccoli, C. Larosa, A.M. Leone, F. Burzotta, C. Trani, G.L. De Maria, C. Hamilton-Craig, F. Crea: Filter no-reflow during percutaneous coronary intervention of saphenous vein grafts: incidence, predictors and effect of the type of protection device. EuroIntervention 7, 955-961 (2011)

  • [44]R. Corbalán, G. Larrain, C. Nazzal, P.F. Castro, M. Acevedo, J.M. Domìniquez, F. Bellolio, M.W. Krucoff: Association of noninvasive markers of coronary artery reperfusion to assess microvascular obstruction in patients with acute myocardial infarction treated with primary angioplasty. Am J Cardiol 88, 342-346 (2001)

  • [45]G. Niccoli, F. Burzotta, L. Galiuto, F. Crea F: Myocardial no-reflow in humans. J Am Coll Cardiol 54, 281-292 (2009)

  • [46]H. Ogawa, T. Akasaka, R. Hattori, Japanese Circulation Society (JCS) Joint Working Group: Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): digest version. Circ J 74, 1745-1762 (2010)

  • [47]C.E. Hamo, M.W. Bloom: Getting to the heart of the matter: An overview of cardiac toxicity related to cancer therapy. Clin Med Insights Cardiol 9, 47-51 (2015)

  • [48]Y. Arima, S. Oshima, K. Noda, H. Fukushima, I. Taniguchi, S. Nakamura, M. Shono, H. Ogawa: Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 54, 512-515 (2009)

  • [49]R. Virmani, A. Farb, A.J. Carter, R.M. Jones: Comparative pathology: radiation-induced coronary artery disease in man and animals. Semin Interv Cardiol 3, 163-172 (1998)

  • [50]M.A. Kurz, K.G. Lamping, J.N. Bates, C.L. Eastham, M.L. Marcus, D.G. Harrison: Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res 68, 847-855 (1991)

  • [51]W.F. Jackson: Potassium channels in the peripheral microcirculation. Microcirculation 12, 113-127 (2005)

  • [52]A. Masumoto, M. Mohri M, H. Shimokawa, L. Urakami, M. Usui, A. Takeshita: Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105, 1545-1547 (2002)

  • [53]A.A. van der Veldt, E. Boven, H.H. Helgason, M. van Wouwe M, J. Berkhof, G. de Gast, H. Mallo, C.N. Tillier, A.J. van den Eertwegh, J.B. Haanen: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99, 259-265 (2008)

  • [54]Pamela Ann Harvey and Leslie Anne Leinwand .Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism. Cardiovascular Research, 107, 66-77(2015)

  • [55]P.G. Camici, F. Crea: Microvascular angina: a women’s affair? Circ Cardiovasc Imaging 8, pii: e003252 (2015)

  • [56]P. Collins P: Role of endothelial dysfunction and oestrogens in syndrome X. Coron Artery Dis 3, 593-598 (1992)

  • [57]E.H. Lieberman, M.D. Gerhard, A. Uehata, B.W. Walsh, A.P. Selwyn, P. Ganz, A.C. Yeung, M.A. Creager: Estrogen improves endotheliumdependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 121, 936-941 (1994)

  • [58]S.C. Adams, R. Schondorf, J. Benoit, R.D. Kilgour: Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: a case-controlled feasibility study. BMC Cancer 15, 414 (2015)

  • [59]R.D. Brook, S. Julius: Autonomic imbalance, hypertension, and cardiovascular risk. Am J Hypertens 13, 112-122 (2000)

  • [60]H.E. Hirvonen, T.T. Salmi, E. Heinonen, K.J. Antila, I.A. Valimaki: Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy. Cancer 64, 801-805 (1989)

  • [61]W.J. Hrushesky, D.J. Fader, J.S. Berestka, M. Sommer, J. Hayes, F.O. Cope. Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. Circulation, 84, 697-707 (1991)

  • [62]E. Ekholm, E. Salminen, H. Huikuri, J. Jalonen, K. Antila, T.A. Salmi, V.T. Rantanen: Impairment of heart rate variability during paclitaxel therapy. Cancer 88, 2149-53 (2000)

  • [63]K.K. Ness, G.T. Armstrong GT: Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation. J Am Coll Cardiol 65, 584-585 (2015)

  • [64]J. Quillen, F. Sellke, P. Banitt, D. Harrison D: The effect of norepinephrine on the coronary microcirculation. J Vasc Res 29, 2-7 (1992)

  • [65]E.O. Feigl: The paradox of adrenergic coronary vasoconstriction. Circulation 76, 737-745 (1987)

  • [66]A. Maseri: Coronary vasoconstriction: visible and invisible. N Engl J Med 325, 1579-1580 (1991)

  • [67]T.P. Broten, J.K. Miyashiro, S. Moncada, E.O. Feigl EO: Role of endothelium-derived relaxing factor in parasympathetic coronary vasodilatation. Am J Physiol 262, H1579–H1584 (1992)

  • [68]E.D.G. Fleurena, Y.M.H. Versleijen-Jonkersa, S. Heskampb, C.M.L. van Herpena, W.J.G. Oyenb, W.T.A. van der Graafa, O.C. Boermanb: Theranostic applications of antibodies in oncology. Mol Oncol 8, 799-812 (2014)

  • [69]A. Busch, S.M. Eken, L. Maegdefessel: Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease.Ann Transl Med 4, 236 (2016)

  • [70]G. Bertoli, C. Cava, I. Castiglioni: MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 5, 1122-1143 (2015)

  • [71]M.W. Bloom, C.E. Hamo, D. Cardinale, B. Ky, A. Nohria, L. Baer, H. Skopicki, D.J. Lenihan, M. Gheorghiade, A.R. Lyon, J. Butler: Cancer therapy-related cardiac dysfunction and heart failure - Part 2: prevention, treatment, guidelines, and future directions. Circ Heart Fail 9, e002843 (2016)

  • [72]T. Hozumi, K. Yoshida, Y. Ogata, T. Akasaka, Y. Asami, T. Takagi, S. Morioka: Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography: comparison with invasive technique. J Am Coll Cardiol 32, 1251-1259 (1998)

  • [73]P. Thavendiranathan, F. Poulin, K.D. Lim, J.C. Plana, A. Woo, T.H. Marwick: Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy : A Systematic Review. J Am Coll Cardiol 65, 2751-2768 (2015)

  • [74]K.S. Shah, A.S. Maisel: Novel biomarkers in heart failure with preserved ejection fraction. Heart Fail Clin 10,471-479 (2014)

  • [75]P.G. Camici, O.E. Rimoldi: The clinical value of myocardial blood flow measurement. J Nucl Med 50, 1076-1087 (2009)

  • [76]P.A. Kaufmann, T. Gnecchi-Ruscone, J.T. Yap, O.E. Rimoldi, P.G. Camici: Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med 40, 1848-1856 (1999)

  • [77]T.H. Schindler, H.R. Schelbert, A. Quercioli, V. Dilsizian: Cardiac PET Imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovas Imaging 3, 623-640 (2010)

  • [78]P. Thavendiranathan, B.J. Wintersperger, S.D. Flamm, T.H. Marwick. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging 6,1080-1091 (2013)

  • [79]R.J. Kim RJ, D.S. Fieno, T.B. Parrish, K. Harris, E.L. Chen, O. Simonetti, J. Bundy, J.P. Finn, F.J. Klocke, R.M. Judd: Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100, 1992-2002 (1999)

  • [80]G. Fragasso, S.L. Chierchia, G. Pizzetti, E. Rossetti, M. Carlino, S. Gerosa, O. Carandente, A. Fedele, N. Cattaneo: Impaired left ventricular filling dynamics in patients with angina and angiographically normal coronary arteries: effect of beta adrenergic blockade. Heart 77, 32-39 (1997)

  • [81]F. Leonardo, G. Fragasso, E. Rossetti, P. Dabrowski, P. Pagnotta, G.M. Rosano, S.L. Chierchia: comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance. Cardiologia 44, 1065-1069 (1999)

  • [82]P.J. Oliveira, J.A. Bjork, M.S. Santos, R.L. Leino, M.K. Froberg, A.J. Moreno, K.B. Wallace: Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 200, 159-168 (2004)

  • [83]P. Georgakopoulos, P. Roussou, E. Matsakas, A. Karavidas, N. Anagnostopoulos, T. Marinakis, A. Galanopoulos, F. Georgiakodis, S. Zimeras, M. Kyriakidis, A. Ahimastos: Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 85, 894-896 (2010)

  • [84]J.Y Choe, A.B. Combs, K. Folkers: Potentiation of the toxicity of Adriamycin by propranolol. Res Commun Chem Pathol Pharmacol. 21, 577-580 (1978)

  • [85]J.C. Kaski, G. Rosano, S. Gavrielides, L. Chen: Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 23, 652-657 (1994)

  • [86]P.G. Camici, P. Marracini, R. Gistri, P.A. Salvadori, O. Sorace, A. L’Abbate: Adrenergically mediated coronary vasoconstriction in patients with syndrome X. Cardiovasc Drugs Ther 8, 221-226 (1994)

  • [87]M.A. Abd El-Aziz, A.I. Othman, M. Amer, M.A. El-Missiry: Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol 21, 469-73 (2001)

  • [88]A. Hiona, A.S. Lee, J. Nagendran, X. Xie, A.J. Connolly, R.C. Robbins, J.C. Wu: Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg 142, 396-403 (2011)

  • [89]H. Buikema, S.H. Monmink, R.A. Tio, H.J. Crijns, D. de Zeeuw, W.H. Gilst: Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol, 1999-2007 (2000)

  • [90]C. Cadeddu, A. Piras, G. Mantovani, M. Deidda, M. Dessì, C. Madeddu, E. Massa, G. Mercuro: Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160, 487 (2010)

  • [91]E. Fábián, A. Varga, E. Picano, Z. Vajo, A. Rónaszéki, M. Csanády: Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am J Cardiol 94, 652-655 (2004)

  • [92]C. Pizzi, O. Manfrini, F. Fontana, R. Bugiardini: Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac syndrome X: role of superoxide dismutase activity. Circulation 109, 53-58 (2004)

  • [93]J. Huelsenbeck, C. Henninger, A. Schad, K.J. Lackner, B. Kaina, G. Fritz: Inhibition of Rac1 signaling by lovastatin protects against anthracyclineinduced cardiac toxicity. Cell Death Dis 2, e190 (2011)

  • [94]S. Seicean, A. Seicean, J.C. Plana, G.T. Budd, T.H. Marwick TH: Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 60, 2384-2390 (2012)

  • [95]P.A. Kaufmann, T. Gnecchi-Ruscone, M. di Terlizzi, K.P. Schäfers, T.F. Lüscher, P.G. Camici Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 102, 1233-1238 (2000)

  • [96]R. Solito, F. Corti, C.H. Chen, D. Mochly-Rosen, A. Giachetti, M. Ziche, S. Donnini: Mitochondrial aldehyde dehydrogenase-2 activation prevents β-amyloidinduced endothelial cell dysfunction and restores angiogenesis. J Cell Sci 126, 1952-1961 (2013)

  • [97]C.H. Chen, G.R. Budas, E.N. Disatnik, T.D. Hurley D. Mochly-Rosen: Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 21, 1493-1495 (2008)

  • [98]W. Ge, M. Yuan, A.F. Ceylan, X. Wang, J. Ren: Mitochondrial aldehyde dehydrogenase protects against doxorubicin cardiotoxicity through a transient receptor potential channel vanilloid 1-mediated mechanism. Biochim Biophys Acta, 1862(4):622-34 (2016)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Mar 2017Review

Cardiotoxicity in oncology and coronary microcirculation: future challenges in theranostics

Giovanni Peretto 1, Davide Lazzeroni 1,2, Carmem Luiza Sartorio 1,*, Paolo Guido Camici 1
Affiliations
Article Info

1 Department of Cardiovascular Diseases, Vita Salute University and San Raffaele Hospital, Milan, Italy

2 Prevention and Rehabilitation Unit, Fondazione Don Gnocchi, Parma, Italy

Abstract

Many of the patients undergoing chemotherapy or radiotherapy for cancer are at increased risk of developing cardiovascular diseases. Recent evidence suggests that cardiac dysfunction and subsequent heart failure are mainly due to vascular toxicity rather than only to due to myocyte toxicity. However, not all of the vascular toxicity of cancer therapies can be explained by epicardial coronary artery disease. In fact, in the last decades, it has been found that myocardial ischemia may occur as a consequence of structural or functional dysfunction of the complex network of vessels, which cannot be seen by a coronary angiography: the coronary microcirculation. Nowadays many diagnostic and therapeutic options are available both in coronary microvascular dysfunction and cardio-oncology. Aim of this review is to suggest future theranostic implications of the relationship between cardiotoxicity in oncology and coronary microvascular dysfunction, showing common pathophysiologic mechanisms, proposing new diagnostic approaches and therapeutic options for cardioprotection.

Keywords

  • Cardio-oncology
  • Vascular Toxicity
  • Microcirculation
  • Coronary Microvascular Dysfunction
  • Theranostics
  • Review

References

Cite

Share